Bavarian Nordic (BAVA) Resumen de Acciones
Bavarian Nordic A/S desarrolla, fabrica y suministra vacunas que salvan vidas. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 6/6 |
| Crecimiento futuro | 1/6 |
| Rendimiento pasado | 1/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
BAVA Community Fair Values
Create NarrativeSee what 44 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Bavarian Nordic A/S
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | DKK 178.70 |
| Máximo en las últimas 52 semanas | DKK 244.80 |
| Mínimo de 52 semanas | DKK 171.30 |
| Beta | 0.94 |
| Cambio en 1 mes | -6.19% |
| Variación en 3 meses | -4.49% |
| Cambio de 1 año | -25.20% |
| Variación en 3 años | 13.75% |
| Variación en 5 años | -36.81% |
| Variación desde la OPV | -29.92% |
Noticias y actualizaciones recientes
Recent updates
Actualización de narrativa • Jun 15
BAVA: Public Preparedness Contracts Will Support 2026 Earnings Upside
Analysts have kept their DKK 273.33 price target for Bavarian Nordic broadly unchanged, citing only minor adjustments to the discount rate, revenue growth assumptions and future P/E estimates in their valuation work. What's in the News Bavarian Nordic secured a government contract valued at over DKK 700 million to supply its MVA-BN smallpox/mpox vaccine in 2026 and 2027, bringing Public Preparedness business contracts for 2026 to about DKK 2,200 million (Source: company announcement, recent news reports).Actualización de narrativa • Jun 01
BAVA: Public Preparedness Contracts And Vaccine Manufacturing Expansion Will Support 2026 Upside
Analysts have nudged their fair value estimate for Bavarian Nordic higher from DKK 268.33 to DKK 273.33. They point to adjusted assumptions around revenue growth, profit margins and future P/E as the main drivers of the updated price target.
Actualización de narrativa • May 16
BAVA: Public Preparedness Contracts And Vaccine Approvals Will Support Higher Future Returns
Analysts have kept their DKK 280 price target for Bavarian Nordic unchanged, pointing to slightly higher assumed revenue growth and profit margins, along with a modestly higher discount rate and a lower future P/E expectation as key inputs behind the refreshed valuation work. What's in the News Bavarian Nordic raised its earnings guidance for 2026, now expecting revenue of DKK 5,500 million to DKK 5,700 million, compared with the earlier range of DKK 5,000 million to DKK 5,200 million.
Actualización de narrativa • Apr 30
BAVA: Vaccine Approvals And Capacity Expansion Will Drive Future Upside
Analysts have kept their DKK 250.00 price target for Bavarian Nordic unchanged. They point to only small tweaks to assumptions on discount rate, revenue contraction, profit margin and future P/E, which they view as largely offsetting each other.Actualización de narrativa • Apr 16
BAVA: Expanded Vaccine Manufacturing Partnership Will Support 2026 Upside
Analysts have kept their DKK price target for Bavarian Nordic effectively unchanged, with a DKK 0.00 net move. Small tweaks to the discount rate and future P/E assumptions offset each other in their updated valuation work.Actualización de narrativa • Apr 01
BAVA: Expanded Vaccine Pipeline And New Contracts Will Support Higher Future Returns
Analysts have raised their price target on Bavarian Nordic from DKK 244.00 to DKK 280.00. They cite updated assumptions for revenue growth, profit margins, and a lower future P/E multiple that they view as better reflecting the company’s current outlook.Actualización de narrativa • Mar 18
BAVA: Expanded Vaccine Partnerships And 2026 Orders Will Support Upside
Analysts have raised their price target on Bavarian Nordic from DKK 265 to about DKK 268, reflecting adjustments to their valuation inputs, including a slightly higher discount rate, a modest change to revenue growth expectations and a marginally different assumed future P/E and profit margin profile. What's in the News Bavarian Nordic expanded its partnership with Serum Institute of India to include full tech transfer and contract manufacturing for the chikungunya vaccine CHIKV VLP, aiming to scale capacity for future supply to endemic low and middle income countries.Actualización de narrativa • Mar 04
BAVA: Buybacks And Latin America Vaccine Deal Will Drive Future Upside
Analysts have maintained their DKK 250 price target on Bavarian Nordic, citing only minor adjustments in assumptions for discount rate, revenue growth, profit margin and future P/E as the reasons for this stable assessment. What's in the News CEO Paul Chaplin plans to step down for personal reasons, and the Board has agreed that he will stay in the role through the end of 2026 or until a successor is appointed.Actualización de narrativa • Feb 18
BAVA: Share Buybacks And Latin America Vaccine Deal Will Support Upside
Analysts now keep their DKK 250 price target for Bavarian Nordic intact, as slightly higher discount and future P/E assumptions together with a modestly stronger profit margin view offset softer revenue growth expectations. What's in the News Bavarian Nordic issued earnings guidance for fiscal 2026, indicating expected revenue in the range of DKK 5,000 million to DKK 5,200 million (Corporate guidance).Actualización de narrativa • Feb 03
BAVA: Latin America Vaccine Deal Will Support Future Earnings Upside
Analysts have nudged their price target on Bavarian Nordic higher to €265, up from €260, citing updated assumptions on discount rates, revenue expectations, profit margins and forward P/E multiples. What's in the News Bavarian Nordic signed an agreement with Eurofarma, giving Eurofarma exclusive rights to sell and distribute the chikungunya vaccine CHIKV VLP, marketed as VIMKUNYA, in Brazil, along with a right of first refusal for future Latin American opportunities, on a transfer price and royalty basis with no upfront or milestone payments (Key Developments).Actualización de narrativa • Jan 20
BAVA: Vaccine Preparedness Contracts And Buybacks Will Support Stronger Long Term Earnings
Analysts have kept their price target for Bavarian Nordic steady at €250.00. They cite a slightly higher assumed discount rate, a smaller expected revenue decline of around 5%, a higher projected profit margin of about 17%, and a lower future P/E assumption near 23x as key inputs behind the unchanged view.Actualización de narrativa • Jan 06
BAVA: HERA Procurement Contract And Mpox Demand Are Expected To Drive Upside
Analysts have kept their price target for Bavarian Nordic unchanged at €260. This reflects only small tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions rather than a shift in their overall view.Actualización de narrativa • Dec 16
BAVA: Mpox Preparedness Contracts Will Underpin Stronger Long Term Earnings Power
Analysts have raised their price target on Bavarian Nordic from approximately $225 to about $250. This reflects a higher justified valuation multiple despite expectations for softer revenue growth and margins.Actualización de narrativa • Dec 02
BAVA: Procurement Agreement And Margin Outlook Signal Upside For Shares
Analysts have raised their price target for Bavarian Nordic from €250 to €260. They cite improvements in projected profit margins and lower expected future price-to-earnings ratios, even though there is a modest increase in the discount rate and a slightly weaker revenue growth outlook.Actualización de narrativa • Oct 24
Local Spread Of New Mpox Strain Will Challenge Future Vaccine Margins
Narrative Update on Bavarian Nordic Analysts have raised their fair value price target for Bavarian Nordic from €244 to €250, citing modest improvements in valuation assumptions and financial projections. What's in the News Officials in California have confirmed community spread of the new clade 1 Mpox strain among residents with no recent international travel.Actualización de narrativa • Aug 27
VIMKUNYA Launch Will Open Markets, But Approval Delays Could Impact Revenues
Despite a deterioration in consensus revenue growth forecasts, a modest improvement in net profit margin has supported a slight increase in Bavarian Nordic's fair value, with the target price rising from DKK234.50 to DKK244.00. What's in the News Nordic Capital and Permira have proposed to acquire Bavarian Nordic for DKK 18.1 billion (DKK 233 per share), a 21% premium to the prior closing price; board and management have agreed to tender their shares, and a delisting is planned upon completion, subject to customary conditions.Artículo de análisis • Jul 28
Bavarian Nordic A/S (CPH:BAVA) Held Back By Insufficient Growth Even After Shares Climb 38%
Despite an already strong run, Bavarian Nordic A/S ( CPH:BAVA ) shares have been powering on, with a gain of 38% in the...Artículo de análisis • Jun 13
Earnings Working Against Bavarian Nordic A/S' (CPH:BAVA) Share Price
When close to half the companies in Denmark have price-to-earnings ratios (or "P/E's") above 16x, you may consider...Artículo de análisis • Apr 03
Here's Why Shareholders May Want To Be Cautious With Increasing Bavarian Nordic A/S' (CPH:BAVA) CEO Pay Packet
Key Insights Bavarian Nordic's Annual General Meeting to take place on 9th of April Total pay for CEO Paul Chaplin...Artículo de análisis • Mar 13
Bavarian Nordic's (CPH:BAVA) Soft Earnings Are Actually Better Than They Appear
The market for Bavarian Nordic A/S' ( CPH:BAVA ) shares didn't move much after it posted weak earnings recently. We...Artículo de análisis • Mar 08
Bavarian Nordic A/S Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Bavarian Nordic A/S ( CPH:BAVA ) came out with its yearly results last week, and we wanted to see how the business is...
Nueva narrativa • Feb 10
Chikungunya Vaccine Launch And Market Expansion Will Open Opportunities But Mpox Demand Uncertainties Could Pose Risks
The chikungunya vaccine launch and expansion into new markets could significantly drive revenue and broaden customer base.Artículo de análisis • Dec 14
Getting In Cheap On Bavarian Nordic A/S (CPH:BAVA) Is Unlikely
With a median price-to-earnings (or "P/E") ratio of close to 14x in Denmark, you could be forgiven for feeling...Artículo de análisis • Nov 16
Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Artículo de análisis • Aug 26
Market Participants Recognise Bavarian Nordic A/S' (CPH:BAVA) Earnings Pushing Shares 53% Higher
Bavarian Nordic A/S ( CPH:BAVA ) shareholders have had their patience rewarded with a 53% share price jump in the last...Artículo de análisis • Aug 25
Bavarian Nordic A/S Just Missed Earnings - But Analysts Have Updated Their Models
Last week, you might have seen that Bavarian Nordic A/S ( CPH:BAVA ) released its quarterly result to the market. The...Rentabilidad de los accionistas
| BAVA | DK Biotechs | Mercado DK | |
|---|---|---|---|
| 7D | 0.2% | -2.4% | -3.1% |
| 1Y | -25.2% | 15.3% | 0.5% |
Rentabilidad vs. Industria: Los resultados de BAVA fueron inferiores a los de la industria Danish Biotechs, que obtuvo un rendimiento del 15.3% el año pasado.
Rentabilidad vs. Mercado: BAVA obtuvo unos resultados inferiores a los del mercado Danish, que fueron del 0.5% el año pasado.
Volatilidad de los precios
| BAVA volatility | |
|---|---|
| BAVA Average Weekly Movement | 3.5% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in DK Market | 7.1% |
| 10% least volatile stocks in DK Market | 2.4% |
Precio estable de las acciones: BAVA no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado Danish.
Volatilidad a lo largo del tiempo: La volatilidad semanal de BAVA (3%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1992 | 1,861 | Paul Chaplin | www.bavarian-nordic.com |
Bavarian Nordic A/S desarrolla, fabrica y suministra vacunas que salvan vidas. La empresa ofrece vacunas no replicantes contra la viruela y la viruela del mono con los nombres IMVAMUNE, IMVANEX y JYNNEOS; vacuna antirrábica para uso humano con el nombre Rabipur/RabAvert; vacuna contra la encefalitis transmitida por garrapatas con el nombre Encepur; Vaxchora, una vacuna oral para la inmunización contra el cólera; y Vivotif/Typhoral, una vacuna oral para la inmunización contra la fiebre tifoidea. También está desarrollando MVA-BN WEV para el tratamiento de los virus de la encefalitis.
Resumen de fundamentos de Bavarian Nordic A/S
| Estadísticas fundamentales de BAVA | |
|---|---|
| Capitalización bursátil | DKK 13.73b |
| Beneficios(TTM) | DKK 1.17b |
| Ingresos (TTM) | DKK 5.96b |
11.6x
Ratio precio-beneficio (PE)2.3x
Ratio precio-ventas (PS)¿Está BAVA sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de BAVA | |
|---|---|
| Ingresos | DKK 5.96b |
| Coste de los ingresos | DKK 3.09b |
| Beneficio bruto | DKK 2.87b |
| Otros gastos | DKK 1.69b |
| Beneficios | DKK 1.17b |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
Aug 21, 2026
| Beneficios por acción (BPA) | 15.37 |
| Margen bruto | 48.11% |
| Margen de beneficio neto | 19.71% |
| Ratio deuda/patrimonio | 0.1% |
¿Cómo se ha desempeñado BAVA a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/04 19:05 |
| Precio de las acciones al final del día | 2026/08/04 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Bavarian Nordic A/S está cubierta por 14 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Jacob Lademann | Carnegie Investment Bank AB |
| Peter Verdult | Citigroup Inc |
| Hakon Hemme Jørgensen | Danske Bank |